Update (December 8): The European Commission has approved Takeda’s dengue vaccine, now known as QDENGA, for use against any of the four dengue serotypes in individuals aged four and older. It is the second approved vaccine for the virus and the first to be approved in Europe without the need for pre-vaccination testing.
The European Medicines Agency has announced today (October 14) its recommendation to approve a dengue vaccine manufactured by Japanese pharmaceutical company Takeda for people four years and older.
Dengue is a mosquito-borne disease that propagates in tropical and subtropical urban environments worldwide, according to the World Health Organization (WHO). The four closely related variants of the virus induce no or mild symptoms in more than 80 percent of those infected, but infections can develop into what is known as severe dengue in some cases. Severe dengue can cause organ impairment, bleeding, and vomiting and is a leading ...
